219 related articles for article (PubMed ID: 23444210)
1. Comparison of fluorescence in situ hybridization, NMP22 bladderchek, and urinary liquid-based cytology in the detection of bladder urothelial carcinoma.
Li HX; Wang MR; Zhao H; Cao J; Li CL; Pan QJ
Diagn Cytopathol; 2013 Oct; 41(10):852-7. PubMed ID: 23444210
[TBL] [Abstract][Full Text] [Related]
2. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
Moonen PM; Kiemeney LA; Witjes JA
Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
4. Analysis of fluorescence in situ hybridization, mtDNA quantification, and mtDNA sequence for the detection of early bladder cancer.
Yoo JH; Suh B; Park TS; Shin MG; Choi YD; Lee CH; Choi JR
Cancer Genet Cytogenet; 2010 Apr; 198(2):107-17. PubMed ID: 20362225
[TBL] [Abstract][Full Text] [Related]
5. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.
Tritschler S; Scharf S; Karl A; Tilki D; Knuechel R; Hartmann A; Stief CG; Zaak D
Eur Urol; 2007 Feb; 51(2):403-7; discussion 407-8. PubMed ID: 16939699
[TBL] [Abstract][Full Text] [Related]
6. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
7. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma.
Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Tews V; Aufderklamm S; Gakis G; Kuehs U; Stenzl A; Schwentner C
Cancer Cytopathol; 2013 May; 121(5):252-60. PubMed ID: 23172833
[TBL] [Abstract][Full Text] [Related]
8. Use of the Nuclear Matrix Protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma.
Xia CS; Fan CH; Su M; Wang QS; Bao HZ
Dis Markers; 2020; 2020():3424039. PubMed ID: 32454904
[TBL] [Abstract][Full Text] [Related]
9. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.
Arora VK; Sarungbam J; Bhatia A; Singh N; Agrawal V; Aggarwal S
Diagn Cytopathol; 2010 Nov; 38(11):788-90. PubMed ID: 20014314
[TBL] [Abstract][Full Text] [Related]
11. [Value of CK20 immunocytochemistry as an adjuvant to urine liquid-based cytology in detection of urothelial carcinoma].
Li M; Li HX; Guo HQ; Zhao H; Zhao LL; Ma JH; Li CL; Cao J; Pan QJ
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):669-73. PubMed ID: 23159079
[TBL] [Abstract][Full Text] [Related]
12. [Value of fluorescence in situ hybridization of urine exfoliative cells in diagnosis of urinary bladder neoplasms].
Chen N; Gong J; Zeng H; Wei Q; Zhu YC; Chen M; Zhou Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):109-13. PubMed ID: 21355314
[TBL] [Abstract][Full Text] [Related]
13. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer.
Marín-Aguilera M; Mengual L; Ribal MJ; Burset M; Arce Y; Ars E; Oliver A; Villavicencio H; Algaba F; Alcaraz A
Cancer Genet Cytogenet; 2007 Mar; 173(2):131-5. PubMed ID: 17321328
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
15. Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder.
Al-Maghrebi M; Kehinde EO; Kapila K; Anim JT
Med Princ Pract; 2012; 21(3):295-7. PubMed ID: 22236881
[TBL] [Abstract][Full Text] [Related]
16. ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study.
Li HX; Li M; Li CL; Ma JH; Wang MR; Rao J; Pan QJ
Anal Quant Cytol Histol; 2010 Feb; 32(1):45-52. PubMed ID: 20701087
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
[TBL] [Abstract][Full Text] [Related]
18. [Numerical aberrations of chromosomes 11 and 17 detected by fish--fluorescence in situ hybridization combined with cytology in exfoliated cells from voided urine in patients with urothelial carcinoma of the bladder].
Asali MG; Kaneti J; Manor E
Harefuah; 2007 Dec; 146(12):914-9, 1000. PubMed ID: 18254439
[TBL] [Abstract][Full Text] [Related]
19. Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.
Smrkolj T; Mihelič M; Sedlar A; Sterle I; Osredkar J; Sedmak B
Clin Chem Lab Med; 2011 Feb; 49(2):311-6. PubMed ID: 21118051
[TBL] [Abstract][Full Text] [Related]
20. [Novel NMP22 quick qualitative analysis (BladderChek NMP22) for the diagnosis of urothelial tumor].
Minagawa T; Nishizawa S; Kamigaito T; Okaneya T
Nihon Hinyokika Gakkai Zasshi; 2006 Jan; 97(1):20-6. PubMed ID: 16485550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
